Big investment push: Sun Pharma Labs to set up Rs 3000 crore facility in MP
Mumbai: Sun Pharma Laboratories Limited, a wholly owned subsidiary of Sun Pharma, is set to establish a Rs 3,000-crore greenfield formulations manufacturing facility in Madhya Pradesh.
The company confirmed that the proposal for the investment to set up the facility has been formally approved by the Board of Directors of Sun Pharma Laboratories.
In a separate development, Medical Dialogues team reported last month reported that Sun Pharma has kept its options open on enhancing its manufacturing footprint in the U.S., even as the U.S. administration's 100% tariff on branded and patented medicines has created uncertainty for global drugmakers.
Read also: Sun Pharma open to enhance manufacturing footprint in US
Meanwhile, Sun Pharma recorded a Rs 3,118 crore net profit in Q2 FY26, marking a 2.56% increase from Rs 3,040 crore in the same quarter last fiscal.
The Mumbai-based company’s revenue from operations climbed to Rs 14,405 crore, compared to Rs 13,264 crore in the same period last fiscal.
Read also: Sun Pharma net profit up 3 percent at Rs 3118 crore in Q2
Sun Pharma is a specialty generics company with a presence in specialty, generics and consumer healthcare products. Sun Pharma’s global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. Its manufacturing facilities are spread across six continents.
